Active substance
Flucloxacillin
- SFDA 5
- NHS prices 6
- WHO EML 1
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| FLOXAPEN 250MG-5ML POWD.FOR SUSP | 50 mg/ml | Powder for suspension · Oral use | 1 Bottle | SAR 53.15 | NCE · Prescription | SMIITHKLINE BEECHAM | Invalid · Not Marketed |
| FLOXAPEN 500MG CAPS | 500 mg | Capsule · Oral use | 20 Blister | SAR 59.05 | NCE · Prescription | SMIITHKLINE BEECHAM | Invalid · Not Marketed |
| FLOXAPEN CAPS 250MG | 250 mg | Capsule · Oral use | 20 Blister | SAR 29.10 | NCE · Prescription | SMIITHKLINE BEECHAM | Invalid · Not Marketed |
| FLOXAPEN SYP 125MG-5ML | 25 mg/ml | Syrup · Oral use | 1 Bottle | SAR 19.46 | NCE · Prescription | SMIITHKLINE BEECHAM | Invalid · Not Marketed |
| FLOXAPEN VIAL 250MG | 250 mg | Solution · Intravenous use | 10 Vial | SAR 57.40 | NCE · Prescription | SMIITHKLINE BEECHAM | Withdrawn by MAH · Not Marketed |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Flucloxacillin 125mg/5ml oral solution | £2.06 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Flucloxacillin 125mg/5ml oral solution sugar free | £3.07 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Flucloxacillin 250mg capsules | £1.39 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Flucloxacillin 250mg/5ml oral solution | £2.30 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Flucloxacillin 250mg/5ml oral solution sugar free | £5.85 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Flucloxacillin 500mg capsules | £2.28 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Therapeutic equivalent to cloxacillin for Bacterial infection of joint; First choice: Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis; First choice: Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis; Second choice: Therapeutic equivalent to cloxacillin for Sepsis without septic shock
Safety signals and safety-related labeling changes
- EMA PRAC 29 Sep 2017 PRAC signal: High anion gap metabolic acidosis (HAGMA)
Action for MAH: update of the product information: Yes - EMA PRAC 6 Apr 2017 PRAC signal: High anion gap metabolic acidosis (HAGMA)
Action for MAH: update of the product information: No - EMA PRAC 27 Oct 2016 PRAC signal: Acute generalised exanthematous pustulosis (AGEP)
Action for MAH: update of the product information: Yes - EMA PRAC 3 Dec 2015 PRAC signal: Metabolic acidosis following administration of flucloxacillin in association with paracetamol
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.